Bristol Myers Squibb and Microsoft partner to scale AI lung cancer detection nationwide

A new collaboration between Bristol Myers Squibb and Microsoft aims to put FDA-cleared radiology artificial intelligence into hospitals and clinics to catch lung cancer earlier and narrow gaps in care. The companies announced on Jan. 20, 2026, that they will deploy algorithms to analyze chest X-ray and CT images through Microsoft’s Precision Imaging Network, a cloud-based radiology platform that Microsoft says is used by more than 80 percent of hospitals in the United States.

The initiative is designed to automate detection and triage by surfacing subtle or incidental nodules and other imaging signs that can precede a diagnosis of non-small cell lung cancer (NSCLC). Beyond image interpretation, partners say the workflows will log incidental findings, prompt follow-up and help guide patients into diagnostic workups and precision therapy pathways when indicated. Bristol Myers Squibb describes the effort as evidence-based and focused on earlier diagnosis to improve outcomes.

"By combining Microsoft’s highly scalable radiology solutions with Bristol Myers Squibb’s deep expertise in oncology and drug delivery, we’ve envisioned a unique AI‑enabled workflow that helps clinicians quickly and accurately identify patients with non‑small cell lung cancer (NSCLC) and guide them to optimal care pathways and precision therapies," said Alexandra Gonçalves, identified in media reports as Vice President and Head of Digital Health, Bristol Myers Squibb.

BMS positioned health equity as central to the program, emphasizing access for rural hospitals and community clinics that lack on-site artificial intelligence teams. "This new Microsoft collaboration reflects our commitment to breaking down barriers and addressing healthcare challenges. At BMS, health equity is not a standalone initiative, it is embedded in everything we do. By deploying this solution and bringing advanced AI tools to the front lines, together we will help to address health disparities in lung cancer," said Andrew Whitehead, VP and Head of Population Health at Bristol Myers Squibb.

The Precision Imaging Network, offered as part of Microsoft for Healthcare radiology solutions, serves as the delivery mechanism, enabling facilities to run third-party imaging algorithms in the cloud and integrate AI outputs into existing reading workflows. The partners say centralized cloud deployment will allow smaller facilities to access advanced tools without maintaining local AI infrastructure.

Important details remain undisclosed. The companies have not named the specific FDA-cleared algorithms to be deployed, disclosed contractual or financial terms, specified pilot sites or provided timelines for rollout. The announcement does not include peer-reviewed clinical outcome data demonstrating that these specific deployments improve survival, nor does it specify metrics that will be used to evaluate real-world impact.

Experts caution that FDA clearance addresses technical safety and performance thresholds but does not replace the need for rigorous clinical validation after deployment. Real-world use will need careful monitoring for false positives, overdiagnosis, workflow disruption and potential biases in algorithm performance across diverse patient populations. Data governance, privacy protections and measures to ensure follow-up care for flagged patients will also be critical to translating earlier detection into better outcomes.

The partnership reflects a broader shift in which pharmaceutical and technology companies are investing in diagnostic AI and cloud platforms to link detection with therapeutic pathways. As the program moves from announcement to deployment, clinicians, health systems and regulators will be watching for evidence that cloud-based AI can reliably accelerate diagnosis and reduce disparities without introducing new harms.